In 1977 we showed that cells of a human lymphocytic leukaemia-derived T line (Molt-4) have receptors for Epstein-Barr virus (EBV). More recently, EBVpositive human T cell lymphomas have been recognized and human T cell lines containing the EBV genome have been established in vitro. To understand better the interaction of EBV with T cells, we decided to determine first whether human peripheral blood T lymphocytes express receptors for EBV. Using flow cytometry we examined the binding of both lymphocyte-transforming (B95-8) and non-transforming (P3HR-1) strains of EBV to T lymphocyte subpopulations, using a double labelling technique with T cellspecific phycoerythrinated monoclonal antibodies (Leu 2a) and fluoresceinated viral preparation. Our results suggest that, in general, about 50% of the CD8 + (or suppressor/cytotoxic) T cell subpopulation from both EBV-seropositive and -seronegative individuals can bind EBV. EBV receptor expression on these T cells was about l0 and 51 times less than that on Molt-4 and Raji (an EBV receptor-positive B cell line) cells, respectively. The specificity of this binding was demonstrated by the inhibition of attachment of viral preparations preincubated with a monoclonal antibody directed against the viral ligand (gp240/350), and by preincubating these target T cells with unlabelled virus. We were unable to detect EBV-induced antigens in infected T cells, suggesting that, as in Molt-4 cells, virus internalization may not occur in fresh T cells and/or that the virus receptor may not be completely functional. We were also unable to detect C3d (or CR2) receptors on these T cells, or to inhibit virus attachment by treating the targets with an anti-CR2 monoclonal antibody (OKB7), suggesting that the EBV receptor on CD8 + peripheral blood lymphocytes is different from that on B cells.
Introduction
Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis (Henle et al., 1968) , is a lymphotropic human herpesvirus that can activate and immortalize B lymphocytes (Greaves et al., 1975; Henle et al., 1967; Menezes et al., 1976) . The EBV genome and its antigen expression are regularly associated with anaplastic nasopharyngeal carcinoma (zur Hausen et al., 1970) and African Burkitt's lymphoma (de Th6 et al., 1978) . EBV has also been associated with a broad spectrum of haematological disorders, especially B cell lymphomas in immunosuppressed patients (Reece et al., 1981; Schnipper, 1981; Purtilo, 1987; Shearer et al., 1985) , thymic carcinomas (Leyvraz et al., 1985) and salivary gland tumours (Saemundsen et al., 1982) . More recently, the EBV genome was found in T cell lymphomas from three patients with chronic EBV infection (Jones et al., 1988) . Furthermore, immortalization of human T cells after EBV DNA transfection has also been reported (Stevenson et al., 1986) .
EBV was originally thought to bind exclusively to B 0000-9068 © 1990 SGM lymphoid cells (Greaves et al., 1975; Jondal & Klein, 1973) . The majority of B lymphocytes that bind EBV are those with surface immunoglobulins (Anderson et al., 1983; Katsuki et al., 1977) and in resting phase (Go-Gag) (Wells et al., 1981) . Interest in an EBV receptor (EBV-R) has grown since the discovery of an association between EBV-R and the C3d (complement) receptor (Freeman et al., 1982; Jondal et al., 1976; Jonsson et al., 1982; Yefenof et al., 1976 Yefenof et al., , 1977 . Better understanding of complement receptors (Fearon, 1985) and the availability of monoclonal antibodies (MAbs) directed against the C3d receptor (CR2) (Fingeroth et al., 1984; Iida et al., 1983; Nemerow et al., 1985; Slaw et al., 1986; has led to the demonstration of the association between EBV-R and the CR2 on B cells. However, there are also reports that show that there are exceptions to this association (Hutt-Fletcher et al., 1983; Patel & Menezes, 1981; Schwaber et al., 1980; Stocco et al., 1988; Takimoto et al., 1986; Tatsumi et al., 1985) , suggesting that, in addition to the CR2 EBV-R, there are other cell membrane molecules to which EBV can bind. In parallel to the demonstration of the EBV-R-CR2 association, the presence of EBV receptors on non-B cells was also reported. The first example was that of Molt-4, a T cell line, which binds EBV but does not undergo virus internalization (Menezes et al., 1977) . It was later found that if EBV-R Raji cel! membranes were experimentally implanted on Molt-4 cells, the latter would express EBV antigens following EBV infection (Shapiro et al., 1982) , suggesting that the Molt-4 EBV-R is not functional in terms of virus penetration. The EBV receptor found on these T cells appears to be different from that on B lymphocytes, as it does not seem to contribute to EBV internalization, and also EBV binding to Molt-4 cells is not affected by a CR2-specific MAb (OKB7) (Stocco et al., 1988) . Of interest in this regard is the recent observation on the expression of CR2 by a T cell line (Fingeroth et al., 1988) , but whether EBV internalization in these CR2-positive T cells occurs was not described by these authors. Therefore, in order to learn more about virus interaction with human T lymphocytes, we analysed EBV binding to fresh human peripheral blood T cell subpopulations. Suspecting that the receptor density on these T cells would probably be lower than that on B lymphocytes, we also investigated this parameter by flow cytometry. We used a double labelling technique with a phycoerythrinated T cell-specific MAb and fluoresceinated viral preparations, to exclude the possibility of interference by contaminating B cells. The results obtained show that about 50% of the CD8 + (Leu2a +) adult peripheral blood T lymphocytes can bind EBV. However, EBV-R expression on these cells occurs at a very low level in comparison to other human EBV-Rpositive (EBV-R ÷) lymphoid targets. Experiments to demonstrate the presence of EBV-induced antigens have produced negative results suggesting that, as in Molt-4 cells, EBV internalization may not take place in these EBV-R ÷ peripheral blood T lymphocytes.
Methods
Cell culture and virus. The human lymphoid cell lines used in these studies were cultured in RPMI 1640 medium supplemented with 10~ heat-inactivated foetal bovine serum and antibiotics, as described previously (Patel & Menezes, 1981) . Cells were incubated in the presence of CO 2 at 37°C and fed twice weekly, when their concentration was adjusted to 2 x 105 cells/ml.
Lymphocyte purification and characterization. Peripheral blood lymphocytes from five healthy-donors (four EBV-seropositive and one EBV-seronegative) were separated by centrifugation on FicollHypaque gradients. B lymphocytes were purified by negative selection (i.e. by lysis of T cells) using OKT3 MAb (Ortho Pharmaceutical) and rabbit complement, as described (Stocco et al., 1988) . T lymphocytes were purified first by passage through a nylon wool column and then by treating the cells with OKB7 MAb (Ortho Pharmaceutical) and rabbit complement; the choice of OKB7 MAb for T cell purification was based on the facts that in preliminary experiments it was found that this antibody did not react with T lymphocytes obtained using the nylon wool column, and also that it had no inhibitory effect on EBV attachment to these cells. The purified T cells were further separated into CD4 ÷ and CD8 ÷ subsets, again with specific MAbs (OKT8 and OKT4, respectively; the latter MAb was also from Ortho Pharmaceuticals) and rabbit complement. The degree of purification of B and T lymphocyte preparations was determined by incubating a sample of these cells with OKB7 and OKT3 MAbs, respectively. The labelled lymphocytes were then revealed with 50 ~tl of a fluoresceinated goat anti-mouse IgG fraction F(ab')2 (Cappel Laboratories) per 106 cells. The cells were then washed three times and resuspended in phosphatebuffered saline (PBS) containing 1% paraformaldehyde (PBS-para 1%) pH 7.2. Each lymphocyte preparation was also tested for the presence of residual contaminant cells, i.e. with the OKT3 and OKB7 MAbs for the B and T lymphocyte preparations, respectively. Viral preparation, titration and fluoresceination. Viral preparation and fluoresceination procedures were described previously (Khdlifa & Menezes, 1982; Patel & Menezes, 1981) . Briefly, the supernatants of 7-day-old cultures of the EBV-producing cell lines P3HR-1 and B95-8 were used as the source of lymphocyte non-transforming (PEBV) and transforming (BEBV) EBV strains, respectively. Cellular debris was eliminated from the supernatants by low-speed centrifugation and membrane (0-45 gin) filtration (Nalgene Labware Department). The virus was then pelleted at 45 000 g for 90 min and resuspended in cold PBS at 1/400 volume of that of the initial supernatant. Titration of the viral preparation was carried out by EBV antigen induction assay in target cell lines (the EBV nuclear antigen induction in B JAB cells and the EBV early antigen induction in Raji cells for the transforming and non-transforming strains, respectively), as previously described (Patel & Menezes, 1981) . For viral fluoresceination, 1 volume of a 2 mg/ml preparation of fluorescein isothiocyanate (FITC, Isomer 1, Sigma) in a carbonate-bicarbonate buffer pH 9.5 was mixed with 9 volumes of the concentrated viral preparation, as described by Khalifa & Menezes (1982) . This mixture was kept at room temperature in the dark for 1 h with frequent agitation. Viral particles were separated from unbound FITC and other impurities by gel chromatography using a Sephadex G-25 column.
Viral binding and neutralization assays.
Fifty gl of the FITC EBV preparation (from previously tested and selected virus lots) diluted with 50 gl of PBS was incubated with 1 x 106 target cells (pellet) for 45 min at 4 °C. The mixture was kept in the dark and agitated every 5 rain. The cells were then washed three times with cold PBS, suspended in PBSpara 1% and analysed in a fluorescence-activated cell sorter (FACS; Becton-Dickinson). The specificity of EBV binding was determined in a blocking assay in which FITC EBV was preincubated with an antimembrane antigen MAb (72A1) specific to EBV gp250, which is known to neutralize EBV (Hoffman et al., 1980) and to inhibit EBV binding (Stocco et al., 1988) .
Double labelling of CD8 + lymphocytes.
The suppressor/cytotoxic (CD8 +) lymphocytes were double-labelled with CD8-specific, phycoerythrinated Leu2a MAbs (Becton-Dickinson, FACS System) and with FITC-EBV. Procedures for the EBV binding assay were the same as those described above. We found in preliminary tests that the Leu2a MAb does not alter FITC-EBV binding to the CD8 ÷ lymphocytes or other targets. Thus the labelling could be done in any preferred order.
Flow cytometry. Calibration procedures and cell analysis were performed on a FACS-III (Becton-Dickinson, FACS System) connected to a realtime acquisition display system (Steward & Price, 1986) . The ion laser beam (Model 164-05, Spectra Physics) was tuned for maximum output at 488 nm and set for 200 nW light output. For detecting fluorescence of microspheres or fluoresceinated cells, a 520 to 560 nm filter package was placed between the beam-splitter and the 'green' photomultiplier tube (FACS III; FI-1 parameter). 'Fluoresbrite' carboxylated microspheres (0.84 + 0.023 ~tm diameter, lot no. 24513, catalogue no. 15702, Polysciences) were used for calibrating the log2 fluorescence settings. According to our standardization procedure, 1 unit of fluorescence (FU) corresponded to approximately 3 × 104 fluorescein molecules. To calibrate the small angle light scatter, beads of 6-28 gm diameter (surface 123.9 ~tm 2) were analysed at channel 26 with a gain of 16 (unless otherwise specified below).
We used 3-parameter, realtime acquisition and display analysis and storage of data obtained from flow cytometric (FACS III) analysis of cells. Microcomputer hardware and software were utilized throughout the design. Software routines for the operator's use were written using a 16-bit version of the FORTH language (68K-FORTH, Empirical Research Group). The realtime routines were written in assembly or machine language for the MC6800, a 16/32 bit microprocessor (Motorola Semiconductors).
Results

FITC-EB V binding to various human lymphoid targets
First, the viral preparations were tested using reference EBV-R + Raji (B) cells and EBV-R-negative (EBV-R-) 1301 (non-B, non-T) cells (Patel & Menezes, 1981; Khalifa & Menezes, 1982) . Results of control experiments on EBV binding to these cells and to CD8 + lymphocytes are given in Table 1 . FACS profiles of FITC-PEBV attachment to EBV-R ÷ cells and the effect of a virus-neutralizing MAb on EBV binding are shown in Fig. 1 . The profile in Fig. 1 (b) illustrates that virtually all Raji cells bound the fluoresceinated virus and their fluorescence level was found to be at 512 FU, compared to 18 FU for control Raji cells (i.e. without FITC-EBV: background fluorescence, Fig. 1 a) . Fig. I (c) shows an inhibition of FITC-EBV binding to Raji cells as a consequence of preincubation of the viral preparation with the EBV-neutralizing MAb 72A 1. Control experi- ments using purified B lymphocytes (i.e. 85% OKB7 ÷) incubated in PBS alone (Fig. 1 d) , or with FITC-PEBV (Fig. 1 e) showed that 90% of these B cells were clearly positive for EBV-binding sites, i.e. with an average fluorescence intensity of 128 FU ( Fig. 1 e) ; in contrast, B cells without FITC-EBV showed a fluorescence intensity of only 4 FU (Fig. 1 d) . Further, the EBV-R-1301 cells did not show any significant fluorescence with FITC-EBV, which demonstrates that the viral preparation used did not bind non-specifically to these cells (Table 1) .
EB V binding to peripheral blood T cells
A purified T lymphocyte population was prepared from peripheral blood lymphocytes (PBL) of a healthy EBVseropositive donor. Ninety-five percent of these cells reacted with OKT3 and 6~ with OKB7 MAbs, respectively, suggesting that less than 6% were not T cells. FACS analysis of FITC-EBV binding to these cells is shown in Fig. 1 (f to h) . Fig. 1 (h) (T cells incubated with FITC-PEBV) demonstrates that about 20% of the T cells showed specific fluorescence and that their fluorescence intensity was about 16 FU, compared to 4 FU for the mock-treated lymphocytes shown in Fig. 1 (f) . This observation indicates that a proportion of T cells from peripheral blood bear the EBV-R. To analyse further this interaction between EBV and T cells, we separated the T cell population into its suppressor/cytotoxic (CD8 +) and helper/suppressor-inducer (CD4 +) components. Fig. 2 shows FACS analysis of FITC-EBV binding to purified CD4 ÷ and CD8 + lymphocytes. The data shown indicate that it is the CD8 ÷ subpopulation, and not the CD4 + lymphocytes, which has binding sites for EBV. The fluorescence of CD4 ÷ cells from four different donors tested was found to be comparable to that of mock-treated T cells. In order to determine the reproducibility of EBV binding to CD8 + cells, we double-labelled the CD8 ÷ lymphocytes of five different donors (i.e. four EBV-seropositive and one EBV-seronegative) with phycoerythrinated Leu2a MAbs and FITC-EBV (B-and PEBV) and studied them by flow cytometry. Representative data obtained using lymphocytes of one of these donors and the respective controls are given in Fig. 1 . These data show that 14~ of the purified T cells were CD8 + (i.e. Leu2a +, right lower frame of Fig. lg) , that 51% of the Leu2a ÷ cells bound the FITC-PEBV (right upper frame of Fig. 1 0, and that this binding was prevented by preincubating the fluoresceinated virus with the 72A1 MAb (down-shift of most of the cells from the right upper frame to lower one; Fig. l j) . Identical results were obtained when the cells of a seronegative individual were analysed (Table 2 ) and there were no Taken together, the results of Fig. 1 and Table 2 suggest that, in general, about 50% of CD8 ÷ human primary lymphocytes can bind EBV. The specificity of this interaction was demonstrated by the inhibition of EBV binding to these cells by the EBV-specific MAb 72A 1 (Fig. l j) , but not by other anti-EBV antibodies that were not directed against the viral ligand (Table 1) . The receptor density found on the surface of these cells was always lower than that found on B lymphocytes and the difference in fluorescence intensity is illustrated in Fig.  1 (e) (B lymphocytes) and 1 (i) (T lymphocytes).
When CD8 ÷ T cells were tested by indirect immunofluorescence for their reactivity with CR2-specific (OKB7) MAbs, negative results were obtained; moreover, as in the case of Molt-4 cells (Stocco et al., 1988) , this MAb had no inhibitory effect on FITC-EBV binding to CD8 ÷ lymphocytes (Table 1) .
Relative EBV-R density on CD8 + T lymphocytes
We also compared the density of EBV-R on these CD8 + cells with that of Raji and Molt-4 cells. The calculation of the surface area of the cells was made using the small * Cell surface area ratio is the quotient between cell surface areas (given in parentheses) of these cells. Fluorescence intensity ratio is the quotient between fluorescence units measured following FITC-BEBV binding to these cells (i.e. figures in parentheses). EBV-R density ratio was determined by dividing the fluorescence intensity ratio by the cell surface area ratio.
angle light scatter (see Methods). The EBV receptor density ratio was expressed as the quotient of fluorescence intensity (FU)/cell surface area. The results show that Molt-4 cells bound 10 times more FITC-EBV than the CD8 + lymphocytes and the former are also 2.16 times larger than the latter, which indicates that Molt-4 cells have 4-7 times higher EBV-R density per unit area than the CD8 ÷ lymphocytes (Table 3 ). The data also show that EBV-R + Raji cells are about 51 times more fluorescent and have an EBV-R density 28 times greater per unit area than the EBV-R + CD8 + lymphocytes.
Finally, when these EBV-R + T cells were tested for their susceptibility to EBV infection (i.e. for EBV nuclear antigen and early antigen induction, and for cell immortalization), negative results were obtained, suggesting that, as in Molt-4 cells (Menezes et al., 1977) , EBV internalization does not occur in CD8 + lymphocytes after virus binding to these targets.
Discussion
The interaction of EBV with human T lymphocytes remains undefined. Our data using flow cytometry demonstrate clearly the presence of EBV-R on a subpopulation of flesh human T cells, the CD8 + T lymphocytes. The possibility that peripheral blood T lymphocytes could bear EBV receptors was first considered because of an earlier observation showing that the human T cell leukaemia-derived Molt-4 line did bind EBV (Menezes et al., 1977) , and more recently because of the recognition of EBV-related T cell lymphomas (Kikuta et al., 1988; Jones et al., 1988) . The technique of double labelling CD8 ÷ lymphocytes has enabled us to exclude the possibility that the positive results were due to contaminating B lymphocytes in the purified T cell preparations. The low EBV-R density on the CD8 ÷ lymphocytes combined with the low percentage of the total EBV-R ÷ in PBL may explain why it might not previously have been possible to observe EBV binding to fresh human T lymphocytes.
Our results also suggest that the T lymphocyte receptor is different from that found on the B lymphocytes for several reasons; the CR2-specific MAb OKB7, which inhibits EBV binding to B cells (Nemerow et al., 1985) , does not recognize (nor affect EBV binding to) CD8 + lymphocytes, as shown above, and also EBV binds to but does not appear to penetrate T cells, whereas viral internalization follows EBV binding to B cells.
In the present study we also found that CD8 + cells had a receptor density lower than any other known EBV-R + lymphoid cell type. However, the possibility that this low apparent density might result from differences in receptor avidity cannot be fully excluded at present. Whether the low EBV-R density is in any way responsible for the lack of T cell permissiveness to EBV also remains to be determined. Earlier observations appear to suggest that the fate of cell surface-bound EBV and its internalization might be determined, at least in part, by the density of virus receptors at the target cell surface (Stocco et al., 1988) . It is not impossible that EBV infects some T cells in vivo, especially those that may express EBV-R at a high density. Such infected cells may acquire a transformed phenotype, as was the case with the T cells transfected in vitro with EBV DNA (Stevenson et al., 1986) . Furthermore, T cell infection in vivo by EBV might also occur when these cells are persistently exposed to this virus, a likely situation in patients with chronic active EBV infection. It may therefore be of interest to determine EBV-R expression on, and virus infectibility of, T lymphocytes from patients who develop EBV genome-positive T cell lymphomas.
During this study we also observed that some other cells, in the enriched T cell population used, bound EBV but did not react with the Leu2a MAb. These cells represented about 10~o of the total enriched T lymphocyte population and can be seen in the left higher frame of Fig. 1 (i) . Because we had about 6~ OKB7 + cells as contaminants in this enriched T cell population, it is possible that most of those unidentified EBV-R + cells were B lymphocytes. If this were the case, it remains to be explained why these contaminant B cells were not found at a fluorescence level of 128 FU, i.e. at the level of purified B cells (as in Fig. 1 e) . Because we used the OKB7 MAb and complement to purify the T cell population, and since this MAb inhibits EBV binding to B lymphocytes, it is possible that those B cells surviving lysis still had OKB7 antibody molecules bound on their surface, which could have inhibited viral attachment to them. Furthermore, these B lymphocytes could have been bearing the least number of CR2/EBV-Rs and thus have been able to avert lysis with the OKB7 MAb and complement. These reasons might explain why the eventual B cell contaminants may be found around the level of 16 FU. About 4~ of the cells (Fig. 1 i, left upper frame) did bind the EBV; these could represent other, as yet unidentified, non-B cell targets.
Taken together, the discovery of EBV-R expression on CD8 + lymphocytes raises new questions; does it represent a new receptor, or is it the same receptor as on B cells, but lacking some epitopes? Can it permit EBV penetration under specific conditions?
The nature and biological function(s) of the EBV receptor on CD8 + peripheral blood human lymphocytes remain to be defined. The biological functions of virus receptors expressed on T cell lines of malignant origin such as Molt-4 (Menezes et al., 1977; Fingeroth et al., 1988) are also unknown. Whether these receptors represent structures functionally active in virus antigen recognition or antiviral lymphocyte responses remains to be investigated.
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